Rossari Biotech · NSE: ROSSARI · BSE: 543213
Q2 FY22 results · Jul–Sep 2021
Rossari Biotech reported revenue from operations of ₹384.52 crore (up 124.0% from Q2 FY21) and net profit of ₹26.23 crore (up 26.5% from Q2 FY21) for Q2 FY22 (Jul–Sep 2021), on a consolidated basis.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 384.52 | 171.67 | +124.0% | 231.11 | +66.4% |
| Other income | 3.96 | 3.95 | +0.3% | 3.07 | +29.0% |
| Total income | 388.48 | 175.62 | +121.2% | 234.18 | +65.9% |
| Profit before share of associates & JVs and tax | 35.75 | 27.76 | +28.8% | 33.24 | +7.6% |
| Share of profit/(loss) of associates & JVs | 0.06 | 0.02 | 0.00 | ||
| Net profit for the period | 26.23 | 20.73 | +26.5% | 24.54 | +6.9% |
| EPS, basic (₹) | 4.77 | 4.07 | +17.2% | 4.52 | +5.5% |
| Net margin (%) | 6.8 | 12.1 | 10.6 |
This company reports a share of profit/(loss) from associates and joint ventures. BSE’s filing format records that share after tax, so it is shown on its own line. The company’s own statement may add it before its “profit before tax” line.
| Item | Q2 FY22 | Q2 FY21 | YoY | Q1 FY22 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 338.61 | 173.71 | +94.9% | 203.95 | +66.0% |
| Other income | 3.28 | 4.99 | −34.3% | 3.27 | +0.0% |
| Total income | 341.89 | 178.69 | +91.3% | 207.22 | +65.0% |
| Profit before tax | 33.47 | 28.88 | +15.9% | 27.00 | +24.0% |
| Net profit for the period | 24.41 | 21.79 | +12.0% | 19.92 | +22.5% |
| EPS, basic (₹) | 4.44 | 4.27 | +4.0% | 3.67 | +21.0% |
| Net margin (%) | 7.2 | 12.5 | 9.8 |
Consolidated
- Filed with BSE
- 02 Nov 2021, 13:01 IST
- Board meeting
- 30 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 02 Nov 2021, 13:01 IST
- Board meeting
- 30 Oct 2021
- Period
- 01 Jul 2021 to 30 Sep 2021
- Review status
- Unaudited
- Source
- XBRL filing on BSE